Navigation Links
Pantec Biosolutions Selects Oclaro Laser Diode Bars for Transdermal Drug Delivery and Tissue Ablation Systems
Date:5/18/2011

or of Industrial and Consumer Lasers at Oclaro.  "The combination of Pantec's P.L.E.A.S.E. platform technology with Oclaro's highly-efficient, high-volume manufacturing capabilities can deliver innovation to the consumer that revolutionizes modern day medical and cosmetic procedures such as drug delivery and tissue ablation."

"We partnered with Oclaro because it delivered the technology and reliable manufacturing excellence we needed, and also worked closely with us to design the best solution for our next generation P.L.E.A.S.E.® products," said Thomas Bragagna, CTO at Pantec Biosolutions.  "As this market continues to expand, we are confident that only a world-class supplier such as Oclaro will enable us to establish a clear leadership position in a space that is poised for explosive growth in the future."

About Oclaro Laser Diode Bars

Oclaro developed a conductively cooled 9xx nm laser diode bar primarily designed for QCW pumping of miniaturized solid state lasers, which is what Pantec required for its P.L.E.A.S.E platform. Oclaro's QCW operation enabled Pantec to develop a compact laser device due to its low cooling requirements, small footprint and extremely high pulse power.

Oclaro laser diode bars feature a highly efficient two sided cooling setup of the 10x12x5mm(3) small footprint diode assembly, which allows for output peak power levels as high as 320W at 300A drive current, 5ms pulse duration and 10% duty cycle. The Er:YAG laser systems developed by Pantec are pumped between 0.1 and 10ms pulse duration and 1-20% duty cycle, making them attractive for medical applications such as transdermal delivery of drugs from large peptides up to whole antibodies, since molecules of this mass can't penetrate passively into the dermis.

To deliver the highest level of reliability, the Oclaro high power laser diodes feature the Oclaro E2 mirror passivation process, which protects the front facet of the bar against
'/>"/>

SOURCE Oclaro, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Protein Sciences Announces Signing of a Forbearance Agreement With Emergent BioSolutions
2. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
3. Valley Baptist Health System Selects Concuitys ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers
4. Commonwealth Care Alliance Selects Casenet To Unify Patient Information and Improve Care for Massachusetts Members
5. MedTechIQ Selects TheBrain to Visualize Expansive Biointellingence Database and Connect the Dots Between Life Sciences, Medicine and Venture Capital
6. BioFlorida Selects Collexis BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations
7. St. Paul Radiology Selects AMICAS
8. DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product
9. Associated Cardiovascular Consultants Selects Sage Intergy EHR to Enhance Quality, Clinical Trial Research and Physician-Patient Relationship
10. FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract
11. Community Care Physicians Selects Allscripts Practice Management System for 190 Physicians in New York Capitol Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014  The 12th ... officially kicks off September 29 at the John ... over Boston for a weeklong ... Cold Chain Global Forum is designed to cover the ... the modern cold chain, all temperature range products, GDP ...
(Date:9/29/2014)... 29, 2014  Perrigo Company plc (NYSE: ... has transferred a portfolio of preclinical research assets, ... of Elan Corporation plc, to drug discovery and ... agreement, Perrigo will receive an upfront payment in ... on any future sales derived from the portfolio. ...
(Date:9/29/2014)... , Sept. 29, 2014  Xcenda, the strategic ... global pharmaceutical sourcing and distribution service companies, recently ... consumption. This research was analyzed in an economic ... associated with an increase in life years and ... at population-level coffee consumption across the ...
(Date:9/29/2014)... 29, 2014 Westbridge Agricultural Products ... EC, a highly effective new tool for organic ... broad spectrum contact herbicide for post-emergent, non-selective weed ... non-food crops. The formulation is an emulsifiable concentrate ... Review Institute (OMRI) for use in organic food ...
Breaking Biology Technology:12th Cold Chain GDP & Temperature Management Logistics Global Forum Officially Kicks Off in Boston 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 3Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 4Coffee Consumption May Increase Survival and Reduce Healthcare Costs 2Coffee Consumption May Increase Survival and Reduce Healthcare Costs 3Westbridge Receives EPA Approval for Its New SUPPRESS™ Herbicide EC 2
... 29, 2012 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... to sell, subject to customary closing conditions, $40 million of ... to purchase shares of its common stock (and the shares ... of the Series 15 Convertible Preferred Stock and exercise and ...
... and TARRYTOWN, New York, May 26, 2012 ... SNY ) and Regeneron Pharmaceuticals, Inc. (NASDAQ: ... a Phase 2 trial of SAR236553/REGN727 (Study 1003, ... SAR236553/REGN727 is a subcutaneously administered, fully-human antibody targeting ...
... known that a diet high in fat and extremely low ... But how the diet worked, and why, was a mysteryso ... called it "Epilepsy,s Big, Fat Miracle." Now, researchers ... an answer, linking resistance to seizures to a protein that ...
Cached Biology Technology:Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 2Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 3Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 4Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 5Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 6Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 2Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 3Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 4Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 5Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 6Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 7Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 8Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 9Reverse engineering epilepsy's 'miracle' diet 2Reverse engineering epilepsy's 'miracle' diet 3
(Date:9/29/2014)... DETROIT In order to support the world,s ... chemicals, polymers and more, new and more efficient ... team of researchers, including several from Wayne State ... of a new grant from the National Science ... Guided Design of Multicomponent Materials for Electrocatalytic Cascade ...
(Date:9/29/2014)... Scientists at Washington State University have concluded ... Smith apples may help prevent disorders associated ... first to assess these compounds in apple cultivars ... print edition of the journal Food Chemistry ... a good source of these nondigestible compounds but ...
(Date:9/29/2014)... Santos has presented Dr. Cristin Samper, president and ... prestigious Order of San Carlos. , The Order ... and military officers who have made outstanding contributions ... international relations. , An international authority on conservation ... to the Colombian Residence in New York to ...
Breaking Biology News(10 mins):Wayne State research aims to develop new, more efficient catalytic materials 2An apple a day could keep obesity away 2
... Interventional Radiology hailed the Sept. 11 decision by ... has oversight of the 24 recognized medical specialty ... for a new Dual Primary Certificate in Interventional ... and its member boards confirmed the benefit to ...
... JEJU, REPUBLIC OF KOREA (September 12, 2012) A ... biologically diverse place on earth, according to the Wildlife ... list of species found there. The announcement was ... gathering of conservationists meeting through Sept. 13 in Jeju, ...
... a man with apparent battle wounds and curvature of the ... the University of Leicester. The University of Leicester has ... King Richard III with Leicester City Council, in association with ... third week, has yielded dramatic findings of human remains which ...
Cached Biology News:Society of Interventional Radiology hails affirmation of specialty's role in patient care 2Society of Interventional Radiology hails affirmation of specialty's role in patient care 3Society of Interventional Radiology hails affirmation of specialty's role in patient care 4Amazing diversity documented in national park 2King Richard III search in new phase after 'discovery has potential to rewrite history' 2King Richard III search in new phase after 'discovery has potential to rewrite history' 3King Richard III search in new phase after 'discovery has potential to rewrite history' 4King Richard III search in new phase after 'discovery has potential to rewrite history' 5King Richard III search in new phase after 'discovery has potential to rewrite history' 6King Richard III search in new phase after 'discovery has potential to rewrite history' 7King Richard III search in new phase after 'discovery has potential to rewrite history' 8King Richard III search in new phase after 'discovery has potential to rewrite history' 9
... PolarScreen Progesterone Receptor (PR) Competitor ... or screening novel progesterone receptor binding ... homogenous assay utilizes a fusion of ... domain of human progesterone receptor [PR-LBD(GST)] ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential Neurological liabilities of compound...
... form from a hematopoietic stem cells called ... the bone surface and lowering the surrounding ... 4.5. The bone mineral is then solubilized ... function is controlled primarily by Macrophage Colony-Stimulating ...
Biology Products: